Skip to content
  1. Home/
  2. Latest news/
  3. What you need to know about Johnson & Johnson’s 2022 second-quarter earnings
Illustration of people examining large charts and graphs

What you need to know about Johnson & Johnson’s 2022 second-quarter earnings

Check out this infographic breakdown of the company’s second-quarter 2022 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

q1-2022-quarterlyearnings-0422.png

This morning, Johnson & Johnson shared its second-quarter performance.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 144,000 employees across the globe working every day to help change the trajectory of health for humanity.

“We are proud to have delivered on the robust operational guidance that we set forth at the beginning of the year, as we’ve continued to advance breakthrough innovation and foster patient access to make a positive impact across many areas of healthcare,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “Johnson & Johnson is strongly positioned to continue making progress on our business priorities, including the creation of the New Consumer Health Company, to deliver both near- and long-term value to all of our Credo stakeholders.”

For more details about the company’s 2022 second-quarter results, and to read a message from Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.


Johnson & Johnson Q2 2022 earnings infographic

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

Johnson & Johnson named to Fortune’s 2025 America’s Most Innovative Companies list

The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.